A Pilot Study to Evaluate the Value of Tc99m Sestamibi Molecular Breast Imaging in a subset of Breast Cancer Patients who have Additional Suspicious Lesions on Pre-Operative MRI

Breast Magnetic Resonance Imaging (MRI) has been shown to be superior to mammography and ultrasound in the detection of breast cancer and is currently recommended as an adjunct to screening in a population of women determined to be at high risk for developing breast cancer. However, its diminished specificity has led to an increased number of biopsies yielding benign results, delays in therapeutic management, and alterations in planned surgical management. Tc99m Sestamibi Molecular Breast Imaging (Tc-MBI) is a nuclear medicine modality developed specifically for breast imaging using two gamma camera heads with cadmium zinc telluride (CZT) detectors.  Tc-MBI has demonstrated significantly higher sensitivity and equivalent specificity in the detection of breast cancer among high-risk women when compared to mammography. We hypothesize that Tc-MBI will likely demonstrate roughly equivalent sensitivity as MRI but higher specificity.   

Our goal is to determine if there is a role for Tc-MBI in the pre-operative evaluation of patients with known breast cancer.  20 patients with newly diagnosed breast cancer women scheduled to undergo biopsy of additional ipsilateral or contralateral suspicious lesions identified on standard of care contrast-enhanced breast MRI will undergo a Tc-MBI molecular breast imaging study. Truth will be obtained from the MRI-initiated biopsy. If pilot results are promising, data will be used to design a large trial.

Funding Agency:  GE Healthcare
PI: Bital Savir-Baruch, MD and Raghu Halkar, MD
Grant Type: Industrial
Funding Period: 11/1/13- 5/1/14

For further information about this study